The Korea Research Institute of Bioscience and Biotechnology is endeavoring to strengthen international research
collaborations in the field of biopharmaceuticals, including cell and gene therapy and bio big data, which have been designated as national strategic technologies

On November 20 (Monday), KRIBB announced that it had signed an MOU with
the Milner Therapeutics Institute (MTI) of the University of Cambridge in the United Kingdom for research cooperation in the field of biopharmaceuticals
and held a joint academic conference to identify areas of strengths of each party as well as common interests.

Since its establishment in 2015, MTI has become one of the top biopharmaceutical research institutes in Europe in a short period of time and
gained unrivaled capacity in developing new drugs based on artificial intelligence technology.

The Milner Affiliate Program, which has helped drive the MTI‘s growth, includes 59 companies, 15 research institutions, and six venture capital firms from around
the world, and it brings together and maximizes the capabilities of industry, academia, research institutes, and hospitals in drug development such as joint
research, clinical trials, and commercialization.

With the signing of this MOU and registration in the Milner Affiliate Program, KRIBB has taken one step closer to achieving cutting-edge biotech innovation.
The institute revealed its plans to undertake joint research with the MTI on promising technologies of the future such as cell and gene therapy, artificial
organs, and bio big data first before gradually expanding cooperation in other fields.

“By working together with the Milner Therapeutics Institute, which plays a pivotal role in the strategic alliances established with global pharmaceutical companies,
bioventures, and major hospitals, we will expand open innovation in the field of cutting-edge biotech and help strengthen Korea’s R&D capabilities in the
biopharmaceutical field,” said Kim Jang-sung, President of KRIBB.